-
Mashup Score: 0Percutaneous Microaxial Left Ventricular Assist Device for Patients With Cardiogenic Shock - 11 month(s) ago
This comparative effectiveness research study compares percutaneous microaxial left ventricular assist device vs alternative treatments among patients presenting with acute myocardial infarction with cardiogenic shock.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0FDA announces recall of Impella heart pumps after 3 patient injuries, nearly 200 complaints - 11 month(s) ago
The FDA has labeled this as a Class I recall, which means using these devices can lead to significant injuries, including death.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#FDA announces recall of Impella heart pumps after 3 patient injuries, nearly 200 complaints #cardiology #cardiotwitter #Impella #Abiomed https://t.co/TP8QqPfcmQ
-
-
Mashup Score: 0Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI - 12 month(s) ago
May 19, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces results of a third-party analysis showing that utilizing Impella during high-risk percutaneous coronary intervention (PCI) procedures may help physicians achieve a more complete revascularization compared to high-risk PCIs supported using an intra-aortic balloon pump (IABP). Previous studies have shown that a more complete…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @Abiomed Abiomed announced results of a third-party analysis showing that utilizing #Impella during high-risk #PCI procedures may help physicians achieve a more complete #revascularization compared to high-risk PCIs supported using an #IABP: https://t.co/Mhsm5XZ4sK
-
-
Mashup Score: 0
April 27, 2023 — Interventional cardiologists at Henry Ford Health are the first in Michigan to treat a patient using the Impella RP Flex with SmartAssist, one of the world’s smallest heart pumps. The innovative pump, which provides temporary right heart mechanical circulatory support, allows Henry Ford Health physicians provide more comprehensive and advanced care options to patients in…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @HFHCardioFellow #Interventional #cardiologists at Henry Ford Health are the first in Michigan to treat a patient using the #Impella RP Flex with #SmartAssist, one of the world’s smallest #heartpumps: https://t.co/qenXy1gpkk
-
-
Mashup Score: 2Cardiac sarcoidosis presenting with cardiogenic shock successfully recovered by Impella and corticosteroid pulse therapy: a case report - 1 year(s) ago
AbstractBackground. Cardiac sarcoidosis (CS) occasionally disrupts circulatory haemodynamics due to arrhythmia or cardiac dysfunction.Case summary. A 70-year-ol
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Cardiac #sarcoidosis presenting with #CS successfully recovered by #Impella and corticosteroid pulse therapy https://t.co/1VRusa0gdz #EHJCaseReports #YesCCT #ImageFirst #echofirst #EPeeps @KardiologieHH @aayshacader @ANazmiCalik @EHJCREiC @TJ_Yeo @cfcamm @FarhanaAra https://t.co/2Rvjj61e9t
-
-
Mashup Score: 0Abiomed at CRT 2023: Benefits of Impella-Supported High Risk PCI and Impella Innovation - 1 year(s) ago
February 24, 2023 — Abiomed, Inc., part of Johnson & Johnson MedTech[1], announced that results from a study on Impella-supported high-risk percutaneous coronary intervention (HRPCI) patients will be presented during the upcoming Cardiovascular Research Technologies (CRT) 2023 Conference in Washington, DC from Feb. 25-28. Abiomed’s booth (#503) and Saturday’s Power Break lunch symposium will…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @Abiomed @CRT_meeting #Abiomed announced that results from a study on #Impella-supported high-risk #percutaneous #coronary #intervention (#HRPCI) patients will be presented at #CRT23: https://t.co/ksR7d3Qjac
-
-
Mashup Score: 1
Percutaneous mechanical circulatory support (MCS) devices have become an integral component of the cardiovascular therapeutic armamentarium. With a growing burd
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Percutaneous mechanical circulatory support device use has high variability across countries: Chinese expert consensus on their use in interventional cardiology. https://t.co/fsmErx1wjU #PCI #Impella #ECMO #IABP #cardiotwitter @ESC_Journals @escardio https://t.co/r7g7PNQv0w
-
-
Mashup Score: 0
Placement of the Impella 5.0 percutaneous left ventricular assist device may cause aortic regurgitation (AR) due to malcoaptation of the aortic leaflets. The authors investigated the prevalence and severity of AR during Impella 5.0 support.
Categories: Anesthesiology, Latest HeadlinesTweet-
👉Seventeen of the 19 patients (89.5%) were diagnosed with #AorticRegurgitation during #Impella 5.0 support. 👉Severity of AR was mild in 11 patients (57.9%) and moderate in 6 (31.6%). https://t.co/wklqkn1w7h https://t.co/lizdtEaiif
-
-
Mashup Score: 3
AbstractBackground and aims. The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for the treatment of cardiogenic shock (CS) may result in lef
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Venoarterial extracorporeal membrane oxygenation (VA-#ECMO) with vs without LV unloading by #Impella: a systematic review and meta-analysis https://t.co/0SDjoseAgw @escardio @ESC_Journals @GianluSava @ehj_ed @JJheart_doc @DrNasrien @rachkataria @RyanTedfordMD @AndrewJSauer https://t.co/4vtjfte4le
-
-
Mashup Score: 0
November 1, 2022 — Abiomed announced that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular (IJ) vein, which enables patient mobility, and has dual-sensor technology…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @Abiomed Abiomed's #Impella #RP_Flex with #SmartAssist has received #FDA pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right #heartfailure for up to 14 days: https://t.co/gxAfCGeAX4
-
The recent observational study on Impella vs IABP or conservative management is, among many other things, a good example that no perfect way to adjust for confounders exist for observational studies! https://t.co/4qKw4TRpK6 @JAMACardio @Abiomed #IABP #Impella https://t.co/F2RFWrgC8B